一项针对慢性免疫性血小板缺血症患者的血小板功能研究,这些患者接受了用血小板蛋白受体激活剂治疗
Christos Stafylidis1, Sevastianos Chatzidavid1, Panagiotis Diamantopoulos1
1Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Thrombosis research
|November 15, 2024
概括
在免疫性血栓缩 (ITP) 中,血栓蛋白质受体激动剂 (TPO-RAs) 似乎没有增强血小板聚合. 相反,TPO-RAs可能会提高血小板衍生的微粒子水平,可能会影响ITP患者的血小板功能.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓形成素受体激动剂 (TPO-RAs) 用于免疫血栓缩 (ITP).
- 已知TPO-RA使用与血栓形成风险增加之间存在关联.
- 目前关于TPO-RA对血小板功能的影响的数据有限.
研究的目的:
- 研究TPO-RAs对ITP患者血小板功能的影响.
- 为了比较TPO-RA治疗患者,接受其他治疗的患者和健康个体之间的血小板聚合和血小板衍生微粒 (PMP) 水平.
主要方法:
- 用光传输聚合计和流动细胞计来评估血小板功能.
- 测量了对ADP,原蛋白和瑞斯托的血小板聚合反应.
- 血小板衍生微粒 (PMP) 水平被量化.
主要成果:
- 与健康个体相比,接受TPO-RA治疗的患者对ADP和原的聚合反应显著减少.
- 在接受其他药物治疗的患者中也观察到减少聚合反应,治疗组之间没有显著差异.
- 与其他治疗组和健康对照组相比,TPO-RA治疗患者的血小板衍生微粒 (PMP) 水平显著升高.
结论:
- TPO-RAs可能不会增强血小板聚合;受损的反应可能是ITP疾病本身的特征.
- TPO-RAs可能会增加PMP水平,这表明它在ITP中调节血小板功能的作用.
- 需要进一步的研究来阐明TPO-RA对血小板功能的确切机制和临床影响.
相关概念视频
01:18Structure and Function of Platelets
1.0K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.0K
01:22Formation of the Platelet Plug
4.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
471
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
471
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
153
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
153
01:28Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
01:16Clot Retraction and Fibrinolysis
4.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.2K